Bone Biologics Corporation
BBLG
$0.6899
$0.02393.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.82% | 3.02% | -38.33% | 18.14% | 34.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.04% | -54.30% | -73.36% | -71.29% | -9.87% |
| Operating Income | -34.04% | 54.30% | 73.36% | 71.29% | 9.87% |
| Income Before Tax | 1.82% | 50.98% | 55.70% | 76.66% | -273.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.82% | 50.98% | 55.70% | 76.66% | -273.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.82% | 50.98% | 55.70% | 76.66% | -273.46% |
| EBIT | -34.04% | 54.30% | 73.36% | 71.29% | 9.87% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 81.83% | 51.65% | 87.14% | 97.63% | -123.08% |
| Normalized Basic EPS | 75.18% | 89.05% | 87.14% | 97.63% | -116.90% |
| EPS Diluted | 81.83% | 51.65% | 87.14% | 97.63% | -123.08% |
| Normalized Diluted EPS | 75.18% | 89.05% | 87.14% | 97.63% | -116.90% |
| Average Basic Shares Outstanding | 440.33% | 347.41% | 244.36% | 883.48% | 651.23% |
| Average Diluted Shares Outstanding | 440.33% | 347.41% | 244.36% | 883.48% | 651.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |